Switch theme
Sign up to access all valuation multiples
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company’s operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
1946
2.1K+
LTM Revenue $576M
LTM EBITDA $80.2M
$747M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kissei Pharmaceutical has a last 12-month revenue of $576M and a last 12-month EBITDA of $80.2M.
In the most recent fiscal year, Kissei Pharmaceutical achieved revenue of $502M and an EBITDA of $124M.
Kissei Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kissei Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $449M | $502M | XXX | XXX | XXX |
| Gross Profit | $208M | $215M | XXX | XXX | XXX |
| Gross Margin | 46% | 43% | XXX | XXX | XXX |
| EBITDA | $118M | $124M | XXX | XXX | XXX |
| EBITDA Margin | 26% | 25% | XXX | XXX | XXX |
| Net Profit | $85.9M | $70.0M | XXX | XXX | XXX |
| Net Margin | 19% | 14% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Kissei Pharmaceutical's stock price is JPY 3635 (or $24).
Kissei Pharmaceutical has current market cap of JPY 156B (or $1.0B), and EV of JPY 112B (or $747M).
See Kissei Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $747M | $1.0B | XXX | XXX | XXX | XXX | $1.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Kissei Pharmaceutical has market cap of $1.0B and EV of $747M.
Kissei Pharmaceutical's trades at 1.3x LTM EV/Revenue multiple, and 9.3x LTM EBITDA.
Analysts estimate Kissei Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Kissei Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $747M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 8.2x | XXX | XXX | XXX |
| P/E | 14.0x | XXX | XXX | XXX |
| P/E/Growth | -0.9x | XXX | XXX | XXX |
| EV/FCF | 22.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKissei Pharmaceutical's NTM/LTM revenue growth is -1%
Kissei Pharmaceutical's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Kissei Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Kissei Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Kissei Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 16% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 44% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kissei Pharmaceutical acquired XXX companies to date.
Last acquisition by Kissei Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Kissei Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Kissei Pharmaceutical founded? | Kissei Pharmaceutical was founded in 1946. |
| Where is Kissei Pharmaceutical headquartered? | Kissei Pharmaceutical is headquartered in Japan. |
| How many employees does Kissei Pharmaceutical have? | As of today, Kissei Pharmaceutical has 2.1K+ employees. |
| Who is the CEO of Kissei Pharmaceutical? | Kissei Pharmaceutical's CEO is Mr. Mutsuo Kanzawa. |
| Is Kissei Pharmaceutical publicy listed? | Yes, Kissei Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of Kissei Pharmaceutical? | Kissei Pharmaceutical trades under 4547 ticker. |
| When did Kissei Pharmaceutical go public? | Kissei Pharmaceutical went public in 1988. |
| Who are competitors of Kissei Pharmaceutical? | Similar companies to Kissei Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kissei Pharmaceutical? | Kissei Pharmaceutical's current market cap is $1.0B |
| What is the current revenue of Kissei Pharmaceutical? | Kissei Pharmaceutical's last 12-month revenue is $576M. |
| What is the current EBITDA of Kissei Pharmaceutical? | Kissei Pharmaceutical's last 12-month EBITDA is $80.2M. |
| What is the current EV/Revenue multiple of Kissei Pharmaceutical? | Current revenue multiple of Kissei Pharmaceutical is 1.3x. |
| What is the current EV/EBITDA multiple of Kissei Pharmaceutical? | Current EBITDA multiple of Kissei Pharmaceutical is 9.3x. |
| What is the current revenue growth of Kissei Pharmaceutical? | Kissei Pharmaceutical revenue growth between 2023 and 2024 was 12%. |
| Is Kissei Pharmaceutical profitable? | Yes, Kissei Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
